Collegium Pharmaceutical (COLL) EBT Margin (2016 - 2026)

Collegium Pharmaceutical's EBT Margin history runs 11 years deep, the most recent figure standing at 9.68% for Q1 2026.

• On a quarterly basis, EBT Margin rose 793.0% year-over-year to 9.68% in Q1 2026; TTM through Mar 2026 was 13.59%, a 107.0% increase from a year earlier, with the FY2025 full-year figure at 11.87%, down 374.0% from the prior year.
• EBT Margin retreated to 9.68% in Q1 2026 per COLL's latest filing, from 14.13% in the prior quarter.
• Across five years, EBT Margin topped out at 46.37% in Q4 2024 and bottomed at 18.92% in Q1 2022.
• The 5-year median for EBT Margin is 9.78% (2024), against an average of 10.67%.
• Biggest YoY gain for EBT Margin was 9589 bps in 2022; the steepest drop was 3656 bps in 2022.
• Year by year, EBT Margin stood at 5.54% in 2022, then soared by 663 bps to 31.19% in 2023, then soared by 49 bps to 46.37% in 2024, then tumbled by 70 bps to 14.13% in 2025, then sank by 31 bps to 9.68% in 2026.
• Per Business Quant, the three latest COLL EBT Margin figures stand at 9.68% (Q1 2026), 14.13% (Q4 2025), and 20.75% (Q3 2025).